The recent development of genomic amplification with transcript sequencing (GAWTS) has greatly facilitated the sequencing of mutant alleles. Accordingly, over a five year period, the causative mutation in 200 unrelated individuals with hemophilia B (100 with severe, 60 with moderate, and 40 with mild disease) will be delineated by sequencing 11 critical regions (2.8 kb) of the factor IX gene. The sequence data will aid in the elucidation of the role of particular sequences in the expression, processing, secretion, or functioning of factor IX. Since X-linked lethal disease such as severe (and to some extend moderate) hemophilia B offer an opportunity to examine mutations that have occurred in the population within the last few generations, analysis of the sequence data will address several questions including: (1) Are there hypermutable or hypomutable sequences? In particular, is CpG a hotspot of mutation as recently suggested for hemophilia A? (2) How do the relative frequencies of mutational types vary with severity of disease? (3) Are there a few mutations which predominate in mild disease while virtually each family has its own mutation in severe disease? (4) Is there genetic heterogeneity, i.e., are there genes on the X chromosome which are necessary for the proper tissue expression or processing of factor IX? In families where the pedigree indicates that the origin of mutation might potentially be determined, GAWTS and DNA haplotype analysis will be performed on appropriate family members in order to estimate the sex ratio of mutation and rate of germ line mosaicism. An additional component of the project involves the development of methodology to further increase the power of GAWTS and to extend the technique to allow the rapid and very sensitive detection of factor IX mRNA, hopefully in readily detectable tissues such as blood, skin, or hair roots.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Feng, Jinong; Drost, Joni B; Scaringe, William A et al. (2002) Mutations in the factor IX gene (F9) during the past 150 years have relative rates similar to ancient mutations. Hum Mutat 19:49-57
Hill, Kathleen A; Sommer, Steve S (2002) p53 as a mutagen test in breast cancer. Environ Mol Mutagen 39:216-27
Sommer, S S; Scaringe, W A; Hill, K A (2001) Human germline mutation in the factor IX gene. Mutat Res 487:1-17
Li, X; Scaringe, W A; Hill, K A et al. (2001) Frequency of recent retrotransposition events in the human factor IX gene. Hum Mutat 17:511-9
Li, X; Drost, J B; Roberts, S et al. (2000) Factor IX mutations in South Africans and African Americans are compatible with primarily endogenous influences upon recent germline mutations. Hum Mutat 16:371
Liu, J Z; Li, X; Drost, J et al. (2000) The human factor IX gene as germline mutagen test: samples from Mainland China have the putatively endogenous pattern of mutation. Hum Mutat 16:31-6
Drost, J B; Scaringe, W A; Jaloma-Cruz, A R et al. (2000) Novel hotspot detector software reveals a non-CpG hotspot of germline mutation in the factor IX gene (F9) in Latin Americans. Hum Mutat 16:203-10
Feng, J; Buzin, C H; Tang, S H et al. (1999) Highly sensitive mutation screening by REF with low concentrations of urea: A blinded analysis of a 2-kb region of the p53 gene reveals two common haplotypes. Hum Mutat 14:175-80
Heit, J A; Ketterling, R P; Zapata, R E et al. (1999) Haemophilia B Brandenberg-type promoter mutation. Haemophilia 5:73-5
Thorland, E C; Drost, J B; Lusher, J M et al. (1999) Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 5:101-5

Showing the most recent 10 out of 37 publications